The Impact of 123I-Meta-Iodobenzylguanidine Scintigraphy on Diagnostics and Follow-up of Neuroblastoma

Authors

  • Jan Abrahamsen Department of Clinical Physiology and Nuclear Medicin, and Department of Pediatry, Odense University Hospital, Odense C, Denmark
  • Bente Lyck Department of Clinical Physiology and Nuclear Medicin, and Department of Pediatry, Odense University Hospital, Odense C, Denmark
  • Jon Helgestad Department of Clinical Physiology and Nuclear Medicin, and Department of Pediatry, Odense University Hospital, Odense C, Denmark
  • Poul Büchler Frederiksen Department of Clinical Physiology and Nuclear Medicin, and Department of Pediatry, Odense University Hospital, Odense C, Denmark

DOI:

https://doi.org/10.3109/02841869509094015

Abstract

The present retrospective study includes all children suspected for having neuroblastoma, admitted to Odense University Hospital in September 1984 through December 1993. Thirty-six children at the age range of 1 month to 14 years and 10 month were investigated with 123I-metaiodobenzylguanidine (MIBG). Nineteen children had histologically verified neuroblastoma. Several MIBG scintigraphic examinations were made in all but one of these 19 children. Positive MIBG scintigraphy strengthened the diagnosis and indicated the volume and location of the tumour at diagnosis and during the treatment period. In a few patients only there was some disagreement between results obtained with MIBG scintigraphy and standard investigations as CT-scanning or ultrasonography. MIBG scintigraphy in all cases turned out to be the most sensitive modality.

 

Downloads

Download data is not yet available.

Downloads

Published

1995-01-01

How to Cite

Abrahamsen, J., Lyck, B., Helgestad, J., & Büchler Frederiksen, P. (1995). The Impact of 123I-Meta-Iodobenzylguanidine Scintigraphy on Diagnostics and Follow-up of Neuroblastoma. Acta Oncologica, 34(4), 505–510. https://doi.org/10.3109/02841869509094015

Issue

Vol. 34 No. 4 (1995): Acta Oncologica

Section

Articles